End Diagnostic Overshadowing:Addressing Ableism in Diagnoses
Launched by RUSH UNIVERSITY MEDICAL CENTER · Sep 20, 2024
Trial Information
Current as of November 02, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "End Diagnostic Overshadowing: Addressing Ableism in Diagnoses," is focused on understanding a problem called diagnostic overshadowing. This occurs when healthcare providers mistakenly attribute new symptoms in people with disabilities (PWD) to their existing disabilities instead of considering other possible conditions. The goal of the study is to identify the reasons behind this issue and find ways to reduce it, especially by creating education programs for healthcare professionals to ensure they are thorough in their diagnoses.
The trial is currently recruiting participants who are between the ages of 3 and 89 and have received billed medical charges. However, individuals under 3 or over 89, as well as those with a secondary diagnosis of dementia, cannot participate. If you or a family member joins the study, you can expect to contribute to important research that aims to improve healthcare for people with disabilities by helping doctors make more accurate diagnoses.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • Patients aged 3-89 who received billed charges
- Exclusion Criteria:
- • Patients under age 3 or over age 89.
- • Patients with secondary diagnosis of dementia as the population is already known to be at increased risk of diagnostic error
About Rush University Medical Center
Rush University Medical Center is a leading academic medical institution located in Chicago, Illinois, dedicated to advancing healthcare through innovative research and clinical trials. As a sponsor of numerous clinical studies, Rush focuses on translating scientific discoveries into effective treatments and improving patient outcomes across a variety of medical disciplines. With a commitment to excellence in patient care, education, and research, Rush leverages its state-of-the-art facilities and a robust network of specialists to conduct comprehensive trials that adhere to the highest ethical and regulatory standards. Through collaboration with a diverse patient population, Rush aims to enhance the understanding of diseases and develop novel therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
Sarah H Ailey, PhD RN
Principal Investigator
Rush University College of Nursing
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported